Effect of low-dose aspirin on reducing cardiovascular events and mortality in individuals with CKD stages 3-5: a meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Chronic kidney disease (CKD) is a global health concern and an independent risk factor for cardiovascular disease. Despite optimal treatments, mortality remains high among CKD patients. This meta-analysis aimed to assess the balance between the cardiovascular benefits and the bleeding risks associated with the use of low-dose aspirin in patients with CKD stages 3-5.

Methods

Randomized controlled trials (RCTs) regarding the use of low-dose aspirin for cardiovascular primary prevention for patients with CKD were searched in PubMed, Embase, and the Cochrane Library. The Cochrane Collaboration RoB 2.0 tool was used to assess the risk of bias of RCTs. Major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and non

SUBMITTER: Lin J 

PROVIDER: S-EPMC11963460 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature